Seer filed a patent infringement lawsuit against Nanomics Biotechnology, targeting multiple Seer intellectual property claims tied to nanoparticle-based protein enrichment technologies. The dispute references US patents covering aspects of enrichment workflows and performance claims such as sensitivity and dynamic range, with Seer’s Proteograph product suite at the center of the litigation. The case follows a PTAB decision that invalidated some claims but upheld others, which Seer said still protect key elements of its technology. Seer’s CEO said the patents have been “battle-tested,” while Nanomics and competing enrichment providers have argued that such rulings clear the field for continued development. For the proteomics tools market, the suit is a signal that the IP landscape remains active even after PTAB proceedings—potentially affecting procurement and adoption decisions by labs and biopharma groups using enrichment-based mass spectrometry workflows.